Endo Pharmaceuticals

Endo became Endo Pharmaceuticals Inc. as a result of a management buyout from DuPont Merck in 1997. Endo is a specialty pharmaceutical company engaged in the research, development, sale and marketing of prescription pharmaceuticals used primarily to treat and manage pain.

Personnel

• Chief financial officer: Charles A. Rowland Jr. (as of December 2006, replacing Jeff Black) ^[1]
• The company's sales force numbers 590 ^[1]

Products^[2]

• Amantadine (Symmetrel®)
• Carbidopa with levodopa (Carbidopa/Levodopa USP)
• Frovatriptan (Frova®)
• Hydrocodone with acetominophen (Zydone®)
• Hydrocodone with homatropine (Hycodan®)
• Lidocaine (Lidoderm®)
  • Lidocaine with tetracaine (Synera®)
• Molindone (Moban®)
• Oxycodone with acetominophen (Percocet®, Endocet®)
• Oxycodone with aspirin (Percodan®)
• Oxymorphone (Opana®)

References

1. ^a b Staff. "Endo Pharmaceuticals names new CFO", Delaware News Journal, December 6, 2006. Retrieved on 2006-12-06. 
2. ^{^}  Product Listing. Endo Pharmaceuticals (2006). Retrieved on 2006-12-06.